Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial
GLPGlobal Partners LP(GLP) Prnewswire·2024-07-22 19:00
  1. GZR18 injection is an investigational drug and has not yet been approved in China.2. Gan & Lee Pharmaceuticals does not recommend the use of any unapproved drugs/indications.The phase IIb clinical trial (CTR20231695) is a multi-center, randomized, double-blind, placebo-controlled study conducted at 25 clinical trial centers in China, recruiting a total of 340 participants. The participants were overweight (BMI≥24 kg/m2) with at least one weight-related comorbidity or obese (BMI≥28 kg/m2) adults with poor ...